A Phase 4 interventional study of Ferric Citrate in Hyperphosphatemia, sponsored by Kaiser Permanente. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2022-01-13.
Sponsored by Kaiser Permanente · Phase 4, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing ferric citrate in Hyperphosphatemia — none open to participants now, none under way, none of them phase 3. ferric citrate · Hyperphosphatemia.
Among the 13 studies testing ferric citrate in Hyperphosphatemia, this one is the 10th largest by enrollment, is one of 2 that started in 2017, is one of 4 in phase 4, and was the 7th registered.
173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.
Browse Hyperphosphatemia studies →None of the 13 studies testing ferric citrate in Hyperphosphatemia is open now. The open studies under Hyperphosphatemia, anywhere →
ferric citrate: first FDA approval 2014 (AURYXIA). What it is approved for, and how studies give it, is on its page →
Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2017.
This study's enrollment of 55 is below the median of 101 across 143 interventional studies indexed under Hyperphosphatemia.
Median enrollment 183 across the 13 interventional studies. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 13 have an industry lead sponsor. The 7 most frequent:
Kaiser Permanente is the lead sponsor of 393 studies on the registry; 43 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
Kaiser Permanente has 1 study filed under Hyperphosphatemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing ferric citrate in Hyperphosphatemia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Transition to Ferric Citrate among Hemodialysis and Peritoneal Dialysis Patients: A Phase 4 "Real World" Experience Study from Kaiser Permanente Southern California
PROTOCOL SUMMARY
Title: Transition to Ferric Citrate among Hemodialysis and Peritoneal Dialysis Patients: A Phase 4 "Real World" Experience Study from Kaiser Permanente Southern California
Short Title: FeCitrate
Protocol Number: KP FeCitrate
Study Phase: 4
Study Site(s): Los Angeles Kaiser Sunset Medical Center
Number of Subjects: 55
Study Arms: 1
Indication: Hyperphosphatemia in end stage renal disease
Primary Purpose: To evaluate the efficacy of ferric citrate for control of serum phosphorus levels and maintenance of adequate iron stores among dialysis-dependent patients before and after conversion from traditional phosphate binders in a "real world" environment
Overview of Study Design: Prospective non-randomized cohort study of 6-9 months duration (active study period 6 months).
Investigational Product Administration: One to two tablets of Ferric Citrate phosphorus binder administered by mouth before every meal to prevent dietary phosphorus absorption.
Study Endpoint: Mean serum phosphorus levels and rate of successful phosphorus control (\<5.5mg/dl) 6 months before and after treatment with ferric citrate
Statistical Methods: Not powered to detect statistical significance
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Auryxia, 210 mg ferric iron tablets equivalent to 1 g of ferric citrate are supplied as 200 tablets in 400-cc high-density polyethylene bottles.
Drug: Ferric Citrate
One to two tablets of Ferric Citrate phosphorus binder administered by mouth before every meal to prevent dietary phosphorus absorption.
Also known as: Auryxia
Phosphorus Levels
Serum phosphorus levels measured by mg/dL from the 6 months prior to enrollment were compared to serum phosphorus levels collected during the 6 months of ferric citrate use
Time frame: 6 months
Intravenous (IV) Iron
The amount of intravenous (IV) iron in mg used per month by participants for 6 months before and 6 months on Ferric Citrate treatment.
Time frame: 6 months
Erythropoiesis Stimulating Agents (ESA) Dose
Mean Erythropoiesis Stimulating Agents (ESA) use from the 6 months prior to enrollment were compared to ESA use during the 6 months of ferric citrate use. The mean ESA dose units given to each participant per month was used in the analysis of this outcome.
Time frame: 6 months
Median Pill Count
median pill count of ferric citrate pills/day required to maintain phosphorus control
Time frame: 6 months
Study subjects who received either hemodialysis (HD) or peritoneal dialysis (PD) at Kaiser Permanente Southern California, Los Angeles Medical Center were eligible for recruitment.
| Milestone | Ferric Citrate - Hemodialysis | Ferric Citrate - Peritoneal Dialysis |
|---|---|---|
| Started | 28 | 27 |
| Completed | 15 | 16 |
| Not completed | 13 | 11 |
| Withdrew: Adverse event | 6 | 8 |
| Withdrew: Withdrawal by subject | 4 | 1 |
| Withdrew: Protocol withdrawal criteria-off drug > 2 weeks | 3 | 2 |
Serum phosphorus levels measured by mg/dL from the 6 months prior to enrollment were compared to serum phosphorus levels collected during the 6 months of ferric citrate use
| mg/dL | Ferric Citrate - Hemodialysis | Ferric Citrate - Peritoneal Dialysis |
|---|---|---|
| Pre-treatment | 5.3 ± 1 | 5.6 ± 0.8 |
| On-treatment | 5.4 ± 1.1 | 6 ± 1.8 |
The amount of intravenous (IV) iron in mg used per month by participants for 6 months before and 6 months on Ferric Citrate treatment.
| mg/mo | Ferric Citrate - Hemodialysis | Ferric Citrate - Peritoneal Dialysis |
|---|---|---|
| Pre-Treatment | 249.2 ± 215.6 | 21.2 ± 43.1 |
| On-Treatment | 102 ± 137.5 | 11.6 ± 33.7 |
Mean Erythropoiesis Stimulating Agents (ESA) use from the 6 months prior to enrollment were compared to ESA use during the 6 months of ferric citrate use. The mean ESA dose units given to each participant per month was used in the analysis of this outcome.
| units/mo | Ferric Citrate - Hemodialysis | Ferric Citrate - Peritoneal Dialysis |
|---|---|---|
| Pre-Treatment | 28761.1 ± 41314.1 | 16724.4 ± 14042.3 |
| Post-Treatment | 16525.8 ± 16917 | 16780.1 ± 13433.7 |
median pill count of ferric citrate pills/day required to maintain phosphorus control
| tablets per day | Ferric Citrate - Hemodialysis | Ferric Citrate - Peritoneal Dialysis |
|---|---|---|
| Phosphate binder pill count prior to Ferric Citrate use | 9.5 (6.8 to 13.8) | 6 (6.0 to 9.0) |
| Phosphate binder pill count during Ferric Citrate use | 6.0 (4.5 to 9.0) | 4.5 (2.0 to 6.0) |
Collected over 7 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ferric Citrate - Hemodialysis | 0/27 (0%) | 7/27 (25.9%) | 23/27 (85.2%) |
| Ferric Citrate - Peritoneal Dialysis | 0/27 (0%) | 10/27 (37%) | 27/27 (100%) |
| Event | Ferric Citrate - Hemodialysis | Ferric Citrate - Peritoneal Dialysis |
|---|---|---|
| Arteriovenous fistulaBlood and lymphatic system disorders | 2/27 | 0/27 |
| Congestive heart failure exacerbationCardiac disorders | 0/27 | 1/27 |
| gallstone pancreatitisGastrointestinal disorders | 0/27 | 1/27 |
| Gastrointestinal HemorrhageGastrointestinal disorders | 1/27 | 0/27 |
| HematocheziaGastrointestinal disorders | 1/27 | 0/27 |
| Abdominal swellingGeneral disorders | 0/27 | 1/27 |
| PeritonitisGeneral disorders | 0/27 | 1/27 |
| Right foot infectionInfections and infestations | 0/27 | 1/27 |
| Chest painMusculoskeletal and connective tissue disorders | 0/27 | 1/27 |
| Chronic back painMusculoskeletal and connective tissue disorders | 1/27 | 0/27 |
| Event | Ferric Citrate - Hemodialysis | Ferric Citrate - Peritoneal Dialysis |
|---|---|---|
| Black stoolGastrointestinal disorders | 20/27 | 25/27 |
| DiarrheaGastrointestinal disorders | 10/27 | 10/27 |
| ConstipationGastrointestinal disorders | 4/27 | 5/27 |
| Nausea, vomitingGastrointestinal disorders | 1/27 | 4/27 |
| Itching/rashSkin and subcutaneous tissue disorders | 2/27 | 4/27 |
| Upper Respiratory InfectionRespiratory, thoracic and mediastinal disorders | 2/27 | 4/27 |
| Decreased appetiteMetabolism and nutrition disorders | 0/27 | 3/27 |
| Bloating/GasGastrointestinal disorders | 2/27 | 2/27 |
| Abdominal painGastrointestinal disorders | 1/27 | 2/27 |
| FatigueGeneral disorders | 2/27 | 0/27 |
A total of 28 Hemodialysis (HD) patients were enrolled. Of these, 2 patients withdrew prior to receiving the study drug, 3 patients withdrew within the first 2 weeks due to adverse event, 2 patients withdrew themselves after 1 day. Only 1 of the 27 Peritoneal Dialysis (PD) patients enrolled in the study withdrew.
| Age, Continuous(years) | Ferric Citrate - Hemodialysis | Ferric Citrate - Peritoneal Dialysis | Total |
|---|---|---|---|
| Mean | 65 ± 13 | 57 ± 14 | 60 ± 14 |
| Sex: Female, Male(Participants) | Ferric Citrate - Hemodialysis | Ferric Citrate - Peritoneal Dialysis | Total |
|---|---|---|---|
| Female | 6 | 7 | 13 |
| Male | 15 | 19 | 34 |
| Race/Ethnicity, Customized(Participants) | Ferric Citrate - Hemodialysis | Ferric Citrate - Peritoneal Dialysis | Total |
|---|---|---|---|
| Asian | 7 | 6 | 13 |
| African American | 6 | 3 | 9 |
| White | 7 | 14 | 21 |
| Unknown Race | 1 | 3 | 4 |
| Hispanic | 7 | 12 | 19 |
| Not Hispanic | 14 | 13 | 27 |
| Unknown Ethnicity | 0 | 1 | 1 |
| Region of Enrollment(participants) | Ferric Citrate - Hemodialysis | Ferric Citrate - Peritoneal Dialysis | Total |
|---|---|---|---|
| United States | 21 | 26 | 47 |
| Body Mass Index (BMI)(kg/m^2) | Ferric Citrate - Hemodialysis | Ferric Citrate - Peritoneal Dialysis | Total |
|---|---|---|---|
| Mean | 28.4 ± 4.7 | 27.8 ± 5.2 | 28.1 ± 4.9 |
| Smoking(Participants) | Ferric Citrate - Hemodialysis | Ferric Citrate - Peritoneal Dialysis | Total |
|---|---|---|---|
| Count of participants | 10 | 6 | 16 |
| Duration on Dialysis(months) | Ferric Citrate - Hemodialysis | Ferric Citrate - Peritoneal Dialysis | Total |
|---|---|---|---|
| Mean | 29 ± 32.1 | 41.4 ± 49.2 | 36.2 ± 42.5 |
| Diabetes(Participants) | Ferric Citrate - Hemodialysis | Ferric Citrate - Peritoneal Dialysis | Total |
|---|---|---|---|
| Count of participants | 8 | 7 | 15 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2017 to primary completion in Sep 2019, 28 months.
Results were first posted in Jan 2022, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric citrate